Category: 1196157-51-3

On July 23, 2020, Watterson, Scott Hunter; O’Malley, Daniel; Gavai, Ashvinikumar V.; Gong, Hua; Tarby, Christine M. published a patent.Electric Literature of 1196157-51-3 The title of the patent was Heterocyclic NLRP3 modulators, for use in the treatment of cancer. And the patent contained the following:

The present invention provides compounds of Formula (I), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human). The experimental process involved the reaction of 2-Amino-6-bromonicotinic acid(cas: 1196157-51-3).Electric Literature of 1196157-51-3

The Article related to heterocyclic nlrp3 modulator cancer, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 1196157-51-3

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 17, 2014, Li, Yun-Long; Burns, David M.; Feng, Hao; Xue, Chu-Biao; Wang, Anlai; Pan, Jun published a patent.HPLC of Formula: 1196157-51-3 The title of the patent was Preparation of bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors for treating proliferative and immune disorders. And the patent contained the following:

The present disclosure describes bicyclic aromatic carboxamide derivatives of formula I (wherein Cy is (un)substituted C3-7 cycloalkyl or (un)substituted 4-10 membered heterocycloalkyl; A1 is N or (un)substituted CH; R2 is H, halogen, C1-6 alkyl, etc.; or A1 and R2 together form part of a ring; R3 is H, halogen or NH2; R4 is H or halogen; and A5-A8 are independently N or (un)substituted CH, with provisos), as well as their compositions and methods of use as Pim kinase inhibitors for treating cancer and other diseases. Synthetic procedures for preparing I are exemplified. Example compound II was prepared in a 6-step synthesis that involved reaction of intermediate III with benzyl [(3S)-1-(3-aminopyridin-4-yl)piperidin-3-yl]carbamate followed by deprotection of the intermediate formed to give II. In Pim kinase inhibitory assays in vitro, II had IC50 values of ≤100 nM for Pim1 and Pim3 and an IC50 value between 100 nM and 1000 nM for Pim2 kinase. The experimental process involved the reaction of 2-Amino-6-bromonicotinic acid(cas: 1196157-51-3).HPLC of Formula: 1196157-51-3

The Article related to preparation bicyclic aromatic carboxamide compound pim kinase inhibitor therapy, proliferative immune disorder treatment bicyclic aromatic carboxamide compound, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 1196157-51-3

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On November 19, 2020, Allen, Bryce K.; Chamberlain, Brian T.; Dwight, Timothy A.; Huang, Huang; Kulkarni, Meghana M.; Lin, Zhixiong; Marino, Kristen A.; Niu, Deqiang; Shechter, Sharon; Swann, Steven published a patent.COA of Formula: C6H5BrN2O2 The title of the patent was Preparation of benzo[b][1,8]naphthyridine acetic acid derivatives as STING modulators useful in treatment and prevention of STING-associated diseases. And the patent contained the following:

The invention relates to preparation of benzonaphthyridine acetic acids(I) or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein. Compounds I wherein X is O, S, CH=CH, etc.; m is 1-3; Y is CN, OH, NH2, etc.; n is 1-4; Z is halo, CN, OH, etc.; etc., are claimed. The example compound II was prepared via multi-step synthesis using Me 2,6-dichloropyridine-3-carboxylic acid as starting material (procedure given). Compounds I were evaluated for their biol. activity (data given). Compounds I are effective modulators of STING, and can be used for the treatment and prevention of diseases caused by or associated with STING. The experimental process involved the reaction of 2-Amino-6-bromonicotinic acid(cas: 1196157-51-3).COA of Formula: C6H5BrN2O2

The Article related to benzonaphthyridine acetic acid preparation sting modulator disease treatment prophylaxis, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.COA of Formula: C6H5BrN2O2

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On October 14, 2021, Reynolds, Dominic; Leger, Serge; Seiler, Michael W.; Agrawal, Anant A.; Vaillancourt, Frederic; Smith, Peter; Hopper, Allen T.; Prajapati, Sudeep; Soueidan, Olivier published a patent.SDS of cas: 1196157-51-3 The title of the patent was Preparation of quinazolinone, phthalazinone and isoquinolinone compounds for modulating splicing. And the patent contained the following:

The present disclosure features compounds I [A = (un)substituted cycloalkyl, heterocyclyl, aryl, or heteroaryl; Rb = B, (un)substituted alkyl, or heteroalkyl; B = (un)substituted cycloalkyl, heterocyclyl, aryl, or heteroaryl; Y = N, (un)substituted CH, or CH2; R2 = (independently) H or alkyl; R3 = (halo)alkyl, halo, cyano, etc.; each of L1 and L2 = (independently) absent, alkylene, heteroalkylene, O, etc.; m = 0-3; n = 0-2] or pharmaceutically acceptable salts, and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof. E.g., a multi-steps synthesis of II, starting from 2-methyl-2H-indazole-5-carboxylic acid, was described. Exemplified compounds I were tested for their RNA splicing modulatory activity (data given for representative compounds I). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of 2-Amino-6-bromonicotinic acid(cas: 1196157-51-3).SDS of cas: 1196157-51-3

The Article related to quinazolinone phthalazinone isoquinolinone preparation splicing nucleic acid rna modulator, premrna dna rna spliceosome modulator quinazolinone phthalazinone isoquinolinone preparation and other aspects.SDS of cas: 1196157-51-3

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On June 23, 2011, Hardy, Larry Wendell; Heffernan, Michele L. R.; Wu, Frank Xinhe; Spear, Kerry L.; Saraswat, Lakshmi D. published a patent.Reference of 2-Amino-6-bromonicotinic acid The title of the patent was Preparation of substituted quinazolinones and their analogs for treating disorders mediated by metabotropic glutamate receptor 5. And the patent contained the following:

The title compounds I [R1 = H, alkyl, heteroalkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, heteroalkyl, etc.; G = CHR2 or NR2 when b and c are both single bonds, or G = CR2 or N when one of b and c is a double bond; Q = NH or CH2 when d and e are single bonds, or N or CH one of d or e is a double bond; X = CH or N when f is a single bond, or C when f is a double bond; Z = CH2, C(O), C(S) or a bond when b is a single bond, or CH or N when b is a double bond; Y1-Y3 = CH, C(halo), C(alkyl), N (provided that no more than one of Y2 and Y3 = N); L1 = CC, HC=CH, CH2CH2, etc.] which modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery, and therefore are useful for the treatment, prevention, and/or management of various disorders, such as neurol. disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer, were prepared Thus, Pd-catalyzed coupling of 7-bromoquinazolin-4(3H)-one with 1-ethynyl-4-fluorobenzene afforded II. Exemplified compounds I were tested in in vitro cell-based assay for modulation of the activation of mGluR5 by glutamate (data given for representative compounds I). Pharmaceutical formulations containing the compounds I and their methods of use are also provided herein. The experimental process involved the reaction of 2-Amino-6-bromonicotinic acid(cas: 1196157-51-3).Reference of 2-Amino-6-bromonicotinic acid

The Article related to quinazolinone pyridoquinazolinone pyridopyrimidinone diazepinoquinazolinone preparation metabotropic glutamate receptor mglur5, neurol neurodegenerative neuropsychiatric learning memory disorder treatment quinazolinone preparation, cognition enhancer gastrointestinal antitumor quinazolinone pyridoquinazolinone pyridopyrimidinone diazepinoquinazolinone preparation and other aspects.Reference of 2-Amino-6-bromonicotinic acid

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary